Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?

被引：0
|
作者：
Desai, Aakash [1 ]
Subbiah, Vivek [2 ,3 ,4 ,5 ]
机构：
[1] Mayo Clin, Div Med Oncol, Rochester, MN USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Network, Houston, TX USA
[5] UT MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, 455 Unit,1515 Holcombe Blvd, Houston, TX 77030 USA
来源：
CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 13期
关键词：
D O I：
10.1158/1078-0432.CCR-23-0746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Genome driven precision oncology has transformed the land-scape of multiple cancers. However, access barriers exist. A recent study exemplified a direct-to-patient outreach program via social media through the implementation of a global program that offered free tumor genomic testing with a focus on rare cancers. See related article by Doe-Tetteh et al., p. 2445
引用
收藏
页码：2339 / 2341
页数：3
相关论文
共 50 条
12345